Amgen Drops GKA Partnership; Array Focusing on Other Drugs
By Catherine Shaffer
Thursday, August 8, 2013
Amgen Inc. quietly backed out of its partnership with Array Biopharma Inc. for development of glucokinase activators (GKA), returning the program, including lead candidate ARRY-403, back to Array. The collaboration dates to 2009, when Amgen paid $60 million up front plus research funding for worldwide rights to Array's small-molecule GKA program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.